SRZN Surrozen, Inc. Stock Quote

SRZN [NASD]

Index	-	P/E	-	EPS (ttm)	-4.24	Insider Own	6.88%	Shs Outstand	34.86M	Perf Week	-2.26%
Market Cap	99.74M	Forward P/E	-	EPS next Y	-1.50	Insider Trans	0.00%	Shs Float	34.61M	Perf Month	-13.67%
Income	-	PEG	-	EPS next Q	-0.47	Inst Own	71.70%	Short Float	0.46%	Perf Quarter	-2.26%
Sales	-	P/S	-	EPS this Y	-137.00%	Inst Trans	-5.13%	Short Ratio	2.83	Perf Half Y	-71.60%
Book/sh	2.94	P/B	0.88	EPS next Y	25.70%	ROA	-	Target Price	16.33	Perf Year	-73.71%
Cash/sh	2.40	P/C	1.08	EPS next 5Y	29.90%	ROE	-	52W Range	1.98 - 14.00	Perf YTD	-59.78%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-81.50%	Beta	-
Dividend %	-	Quick Ratio	11.80	Sales past 5Y	-	Gross Margin	-	52W Low	30.81%	ATR	0.23
Employees	83	Current Ratio	11.80	Sales Q/Q	-	Oper. Margin	-	RSI (14)	47.90	Volatility	6.15% 8.46%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	26.30%	Profit Margin	-	Rel Volume	0.01	Prev Close	2.54
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	56.35K	Price	2.59
Recom	1.00	SMA20	0.49%	SMA50	-10.19%	SMA200	-54.18%	Volume	445	Change	1.78%

Oct-11-21

Initiated

BofA Securities

Buy

$11

Sep-15-21

Initiated

Guggenheim

Buy

$20

Sep-07-21

Initiated

Stifel

Buy

$19

May-24-22 08:00AM	Surrozen Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW) GlobeNewswire -5.75%
May-18-22 08:00AM	Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis GlobeNewswire +7.29%
May-16-22 08:00AM	Surrozen Publishes Article in Cellular and Molecular Gastroenterology and Hepatology Demonstrating that SZN-1326, a Selective Wnt Mimetic, Stimulated Robust Colon Epithelial Regeneration and Ameliorated Colitis in an Acute Model of Inflammatory Bowel Disease (IBD) GlobeNewswire
May-11-22 08:00AM	Surrozen Reports First Quarter 2022 Financial Results GlobeNewswire -8.74%
May-05-22 08:00AM	Surrozen to Present at the BofA Securities 2022 Healthcare Conference GlobeNewswire -12.88%
May-02-22 08:00AM	Surrozen Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Retinopathy at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting GlobeNewswire
Mar-24-22 08:00AM	Surrozen Reports Fourth Quarter and Full Year 2021 Financial Results GlobeNewswire -6.03%
Jan-20-22 09:00AM	Heartland Express, Inc. Reports Fourth Quarter and Annual Financial Results which includes All-Time Record High Annual Earnings Per Share GlobeNewswire -7.62%
Jan-10-22 08:00AM	Surrozen Announces Key 2022 Milestones for Lead Programs and Acceleration of Research Pipeline GlobeNewswire
Jan-05-22 08:00AM	Surrozen to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Nov-15-21 04:00PM	Surrozen Reports Third Quarter 2021 Financial Results GlobeNewswire
08:00AM	Surrozen to Present at The Piper Sandler 33rd Annual Healthcare Conference GlobeNewswire
08:00AM	Surrozen Presents Data Supporting Potential of SZN-043 at The Liver Meeting 2021, the Annual Meeting of the American Association for the Study of Liver Diseases GlobeNewswire
Nov-11-21 10:51AM	How Many Surrozen, Inc. (NASDAQ:SRZN) Shares Do Institutions Own? Simply Wall St. +19.50%
Nov-05-21 08:00AM	Surrozen to Present at The Stifel 2021 Virtual Healthcare Conference GlobeNewswire
Oct-05-21 04:30PM	Surrozen Presented Data Supporting Potential of SZN-1326 at the 2021 United European Gastroenterology Week GlobeNewswire -5.75%
Sep-23-21 08:30AM	Surrozen Announces Appointment of Liz Nguyen as Vice President and Head of Human Resources GlobeNewswire -9.07%
Aug-11-21 05:30PM	Surrozen Debuts as Publicly Traded Leader in Wnt Biology and Tissue Regeneration GlobeNewswire

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience